In:
The Pharmacogenomics Journal, Springer Science and Business Media LLC, Vol. 20, No. 5 ( 2020-10), p. 621-628
Abstract:
A systematic review of pharmacogenomic studies capturing adverse drug
reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies
were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the
inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone
mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication.
Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal
suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting
(theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
Type of Medium:
Online Resource
ISSN:
1470-269X
,
1473-1150
DOI:
10.1038/s41397-019-0140-y
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2020
detail.hit.zdb_id:
2051501-7
SSG:
15,3
Bookmarklink